The Current Ratio as of November 2024 (TTM) for Larimar Therapeutics, Inc. (LRMR) is 13.10

According to Larimar Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 13.10. This represents a change of 1.73% compared to the average of 12.87 of the last 4 quarters.

Larimar Therapeutics, Inc. (LRMR) Historical Current Ratio (quarterly & annually)

How has LRMR Current Ratio performed in the past?

The mean historical Current Ratio of Larimar Therapeutics, Inc. over the last ten years is 10.57. The current 13.10 Current Ratio has changed 12.29% with respect to the historical average. Over the past ten years (40 quarters), LRMR's Current Ratio was at its highest in in the March 2015 quarter at 24.80. The Current Ratio was at its lowest in in the March 2019 quarter at 0.32.

Larimar Therapeutics, Inc. (LRMR) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Larimar Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Larimar Therapeutics, Inc. (LRMR) Average Current Ratio

How has LRMR Current Ratio performed in the past?

The current Current Ratio of Larimar Therapeutics, Inc. (LRMR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Larimar Therapeutics, Inc. (LRMR) Current Ratio vs. Peers

How is LRMR’s Current Ratio compared to its peers?

Larimar Therapeutics, Inc.’s Current Ratio is less than Vaxcyte, Inc. (17.88), greater than Syndax Pharmaceuticals, Inc. (6.99), greater than Merus N.V. (8.32), greater than Sutro Biopharma, Inc. (3.09), greater than Immuneering Corporation (7.99), less than Centessa Pharmaceuticals plc (21.52), greater than Celcuity Inc. (10.36), less than Ikena Oncology, Inc. (15.32), greater than Spero Therapeutics, Inc. (2.68), greater than Bolt Biotherapeutics, Inc. (3.16), greater than Coherus BioSciences, Inc. (1.25), greater than Gracell Biotechnologies Inc. (7.73), less than Neoleukin Therapeutics, Inc. (15.33), greater than Surrozen, Inc. (7.40), less than Keros Therapeutics, Inc. (19.03), greater than Kezar Life Sciences, Inc. (7.65), greater than Cabaletta Bio, Inc. (8.11), greater than Homology Medicines, Inc. (4.19), less than Day One Biopharmaceuticals, Inc. (14.62), greater than Alector, Inc. (3.29),

Build a custom stock screener for Larimar Therapeutics, Inc. (LRMR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Larimar Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Larimar Therapeutics, Inc. (LRMR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Larimar Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.